September 29, 2017 / 11:10 AM / 2 months ago

Zogenix epilepsy drug meets main goal in late-stage trial

Sept 29 (Reuters) - Zogenix Inc said on Friday its experimental treatment for a rare form of epilepsy met the main goal in a late-stage study.

The drug was being compared with a placebo in children having Dravet syndrome, a genetic dysfunction in the brain that leads to potentially fatal, long-lasting, fever-related seizures that do not respond to standard treatment. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below